Loading
AZD5492 is an experimental T-cell engager from AstraZeneca in phase 2 trials, aimed at CD20.
AZD5492 is a T-cell engager developed by AstraZeneca. Its target is CD20 (the sponsor names CD20). The sponsor states: A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies. ClinicalTrials.gov describes the intervention as: CD8/TCR based T-cell engaging antibody targeting CD20, which is administered subcutaneously. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06542250, plans to enrol 174 participants with primary completion expected 2029-12-18. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
A CD8/TCR-based T-cell engaging antibody targeting CD20, administered subcutaneously to redirect T cells against CD20-positive B-cell malignancies. Connects to CD20.
1.One arm of AZD5492 binds CD20 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"AZD5492" OR ABSTRACT:"AZD5492") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about AZD5492, not a curated reading list.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares CD20 and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.